354 related articles for article (PubMed ID: 27899296)
1. Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story.
Vermeiren Y; De Deyn PP
Neurochem Int; 2017 Jan; 102():22-32. PubMed ID: 27899296
[TBL] [Abstract][Full Text] [Related]
2. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
[TBL] [Abstract][Full Text] [Related]
3. Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.
Espay AJ; LeWitt PA; Kaufmann H
Mov Disord; 2014 Dec; 29(14):1710-9. PubMed ID: 25297066
[TBL] [Abstract][Full Text] [Related]
4. Locus Coeruleus Pathology Indicates a Continuum of Lewy Body Dementia.
Tilley BS; Patel SR; Goldfinger MH; Pearce RKB; Gentleman SM
J Parkinsons Dis; 2021; 11(4):1641-1650. PubMed ID: 34334423
[TBL] [Abstract][Full Text] [Related]
5. Locus coeruleus.
Benarroch EE
Cell Tissue Res; 2018 Jul; 373(1):221-232. PubMed ID: 28687925
[TBL] [Abstract][Full Text] [Related]
6. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia.
Del Tredici K; Braak H
J Neurol Neurosurg Psychiatry; 2013 Jul; 84(7):774-83. PubMed ID: 23064099
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S; Raymick J; Imam S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
[TBL] [Abstract][Full Text] [Related]
8. Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
Lin CP; Knoop LEJ; Frigerio I; Bol JGJM; Rozemuller AJM; Berendse HW; Pouwels PJW; van de Berg WDJ; Jonkman LE
Mov Disord; 2023 Sep; 38(9):1655-1667. PubMed ID: 37347552
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
10. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
Chan-Palay V; Asan E
J Comp Neurol; 1989 Sep; 287(3):373-92. PubMed ID: 2570794
[TBL] [Abstract][Full Text] [Related]
11. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra.
Bing G; Zhang Y; Watanabe Y; McEwen BS; Stone EA
Brain Res; 1994 Dec; 668(1-2):261-5. PubMed ID: 7704612
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism.
Kreiner G; Rafa-Zabłocka K; Barut J; Chmielarz P; Kot M; Bagińska M; Parlato R; Daniel WA; Nalepa I
Sci Rep; 2019 Mar; 9(1):5262. PubMed ID: 30918302
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease.
Farrand AQ; Verner RS; McGuire RM; Helke KL; Hinson VK; Boger HA
Brain Stimul; 2020; 13(5):1323-1332. PubMed ID: 32629028
[TBL] [Abstract][Full Text] [Related]
14. Sustained chemogenetic activation of locus coeruleus norepinephrine neurons promotes dopaminergic neuron survival in synucleinopathy.
Jovanovic P; Wang Y; Vit JP; Novinbakht E; Morones N; Hogg E; Tagliati M; Riera CE
PLoS One; 2022; 17(3):e0263074. PubMed ID: 35316276
[TBL] [Abstract][Full Text] [Related]
15. Copper pathology in vulnerable brain regions in Parkinson's disease.
Davies KM; Bohic S; Carmona A; Ortega R; Cottam V; Hare DJ; Finberg JP; Reyes S; Halliday GM; Mercer JF; Double KL
Neurobiol Aging; 2014 Apr; 35(4):858-66. PubMed ID: 24176624
[TBL] [Abstract][Full Text] [Related]
16. Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia.
Walter U; Dressler D; Wolters A; Wittstock M; Greim B; Benecke R
J Neurol; 2006 Apr; 253(4):448-54. PubMed ID: 16267638
[TBL] [Abstract][Full Text] [Related]
17. Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling.
Szot P; Knight L; Franklin A; Sikkema C; Foster S; Wilkinson CW; White SS; Raskind MA
Neuroscience; 2012 Aug; 216():143-57. PubMed ID: 22542679
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
19. [Dynamic changes of locus coeruleus damage in Parkinson's disease-like mice induced by paraquat].
Zhang BY; Wang KD; Zhang BF; Tian T; Wang YF; Huang M
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Apr; 40(4):260-266. PubMed ID: 35545591
[No Abstract] [Full Text] [Related]
20. Parkinson's disease: Autoimmunity and neuroinflammation.
De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
